

The Impact of Systemic Lupus Erythematosus on the Clinical Course of Anticardiolipin Antibody-Positive Patients: Results From the Anticardiolipin Clinical Trials and International Clinical Database and Registry

Arthritis Care and Research

71, 134-141

DOI: [10.1002/acr.23584](https://doi.org/10.1002/acr.23584)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 376-386.	1.4	21
2	Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2019, 31, 231-240.	4.3	22
3	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	3.4	39
4	The Weight of IgA Anti- β 2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8972.	4.1	23
5	Management of Non-criteria Manifestations in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2020, 22, 51.	4.7	22
6	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	1.6	28
7	Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population. <i>Frontiers in Immunology</i> , 2020, 11, 568503.	4.8	9
8	Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4120.	4.1	13
9	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1387-1393.	3.4	16
10	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021, 23, 45.	4.7	9
11	Risk of Systemic Lupus Erythematosus in Patients With Anti-phospholipid Syndrome: A Population-Based Study. <i>Frontiers in Medicine</i> , 2021, 8, 654791.	2.6	7
12	B cells in primary antiphospholipid syndrome: Review and remaining challenges. <i>Autoimmunity Reviews</i> , 2021, 20, 102798.	5.8	10
13	S�ndrome antifosfol�pido (SAF): diferencias cl�nicas e inmunoserol�gicas entre SAF primario y secundario en una cohorte colombiana. <i>Revista Colombiana De Reumatolog�a</i> , 2021, 28, 191-196.	0.1	0
14	Antiphospholipid syndrome (APS): Clinical and immunoserological differences between primary and secondary APS in a Colombian cohort. <i>Revista Colombiana De Reumatolog�a (English Edition)</i> , 2021, 28, 191-196.	0.0	1
15	Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2021, 73, 1780-1790.	5.6	16
16	Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding <i>HLA�DRB1</i> Genotype Associations and Immunological and Clinical Manifestations. <i>ACR Open Rheumatology</i> , 2022, 4, 27-39.	2.1	25
17	Systemic Lupus Erythematosus, Mixed Connective Tissue Disease and Antiphospholipid Syndrome. , 2021, , 77-93.		1
18	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.9	128

#	ARTICLE	IF	CITATIONS
19	Eltrombopag-Induced Thrombocytosis and Thrombosis in Patients With Antiphospholipid Syndrome and Immune Thrombocytopenic Purpura. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962110605.	0.6	3
20	Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. <i>Journal of Autoimmunity</i> , 2022, 128, 102813.	6.5	37
21	An Update on Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2021, 23, 84.	4.7	20
22	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€Registryâ€™). <i>Lupus Science and Medicine</i> , 2022, 9, e000633.	2.7	9
23	Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	9
24	Suspected COVID-19 Immunization-Induced Probable Catastrophic Antiphospholipid Syndrome. <i>Cureus</i> , 2022, , .	0.5	1
25	IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9432.	4.1	8
26	Digital ulcers as presenting symptom of secondary antiphospholipid syndrome. <i>JAAD Case Reports</i> , 2022, 29, 1-5.	0.8	1
27	Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 417		
28	Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis. <i>Current Problems in Cardiology</i> , 2023, 48, 101672.	2.4	8
29	Reduced circulating Tregs and positive pANCA were robustly associated with the occurrence of antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Lupus</i> , 2023, 32, 746-755.	1.6	0
31	Accelerated Atherosclerosis and Management of Cardiovascular Risk in Autoimmune Rheumatic Diseases: An Updated Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101999.	2.4	4
32	Assessing disease activity and damage in antiphospholipid syndrome. <i>Clinical Immunology</i> , 2023, 255, 109727.	3.2	1
33	Anti-Î²2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China. <i>Lupus Science and Medicine</i> , 2023, 10, e000924.	2.7	0
34	Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	2.7	0
35	Platelets and Thrombotic Antiphospholipid Syndrome. <i>Journal of Clinical Medicine</i> , 2024, 13, 741.	2.4	0
36	Female patients with systemic lupus erythematosus (SLE)-associated antiphospholipid syndrome (APS) have a lower ovarian reserve than either primary APS or SLE patients. <i>Journal of Laboratory Medicine</i> , 2024, 48, 83-90.	1.1	0
37	The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. <i>Rheumatology</i> , 2024, 63, SI72-SI85.	1.9	1